TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7758260
Drug: Post‐prandial intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐prandial intravenous insulin
Study: 2083922
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (20 mg infused intravenously)
Study: 227180
Drug: 1 gm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm. l‐tryptophan
Study: 227180
Drug: 3 gms.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 gms. l‐tryptophan
Study: 19386792
Drug: Exogenous PTH
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Exogenous PTH administered subcutaneously to male Sprague-Dawley rats
Study: 17244215
Drug: Timolol‐dorzolamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol‐dorzolamide combination twice daily
Study: 15821205
Drug: IV ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ampicillin/sulbactam (normal dose)
Study: 15821205
Drug: IV ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ampicillin/sulbactam (half dose)
Study: 9219402
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg daily for 5 days
Study: 9219402
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg four times a day for 5 days
Study: 7715474
Drug: 1.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/day percutaneous 17 beta‐oestradiol (E2) for 36 months
Study: 7715474
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day oral conjugated oestrogens (CEE) for 24 months
Study: 23478748
Drug: ω-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 PUFA supplementation (1.2 g per day)
Study: 22614774
Drug: Laninamivir octanoate
Normalized name: Laninamivir octanoate
DrugBank: Laninamivir octanoate (DB11888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laninamivir octanoate (LO) 20 or 40 mg (depending on age), single inhalation
Study: 22614774
Drug: Zanamivir (ZN)
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir (ZN) 20 mg, inhaled twice daily for 5 days
Study: 19610037
Drug: Herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal therapy treatment (PT)
Study: 19610037
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic treatment (C)
Study: 15936869
Drug: Darifenacin immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin immediate release (IR) 2.5 mg t.i.d.
Study: 15936869
Drug: Oxybutynin 2.5
Normalized name: oxyBUTYnin 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 2.5 mg t.i.d.
Study: 15936869
Drug: Darifenacin controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled release (CR) 15 mg q.d.
Study: 15936869
Drug: Darifenacin CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin CR 30 mg q.d.
Study: 15936869
Drug: Darifenacin CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin CR (both doses)
Study: 15936869
Drug: Oxybutynin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (both doses)
Study: 15229420
Drug: Endoscopic epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic epinephrine injection (1:10,000 solution, mean volume 18.0 mL)
Study: 10743448
Drug: Fentanyl 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.15 mg followed by fentanyl 0.05 mg
Study: 10743448
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg followed by morphine 7 mg
Study: 2413307
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg i.v.)
Study: 19151305
Drug: Ultrasound-guided anterior
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided anterior approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Study: 19151305
Drug: Ultrasound-guided posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided posterior (subgluteal) approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Study: 16512755
Drug: Chlorhexidine varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine varnish administration
Study: 3773023
Drug: Intravenous solution
Normalized name: Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution (IV) only
Study: 3773023
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration along with intravenous solution (ORS/IV)
Study: 20728874
Drug: Sleep therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep therapy
Study: 15717256
Drug: Once-daily emtricitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily emtricitabine, didanosine, and efavirenz (n=178)
Study: 15717256
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) based regimen (n=177)
Study: 15717256
Drug: Once-daily emtricitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily emtricitabine, didanosine, and efavirenz
Study: 12860502
Drug: Linezolid (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (i.v. 600 mg BID for 7-28 days or switched to oral 600 mg BID)
Study: 12860502
Drug: Teicoplanin (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (i.v. alone or switched to i.m. administration)
Study: 10493326
Drug: Integrated outpatient
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated outpatient treatment (IOT)
Study: 10493326
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard alcoholism treatment)
Study: 1836425
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg/4 weeks s.c., n = 20)
Study: 1836425
Drug: Danazol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (2 x 400 mg/day p.o., n = 13)
Study: 7042363
Drug: Indoprofen 300
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 300 mg/day
Study: 7042355
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg/day
Study: 15367922
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol/day
Study: 15367922
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol/day
Study: 12218503
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with bolus intravenous doses of 1 mg morphine for 3 days
Study: 9800817
Drug: Polytetrafluoroethylene patches
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene patches
Study: 9800817
Drug: Polyglycolic acid
Normalized name: polyglycolic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyglycolic acid patches
Study: 2777422
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of sustained-release urapidil (Ebrantil 60)
Study: 2777422
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg urapidil (fast-release tablet)
Study: 23934387
Drug: US-guided IA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided IA injection
Study: 23934387
Drug: Palpation-guided IA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided IA injection
Study: 23934387
Drug: Both US-guided
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both US-guided and palpation-guided IA injections
Study: 15673896
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine (30 mg)
Study: 15673896
Drug: Procaine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine (80 mg)
Study: 14738262
Drug: Midazolam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.02 mg x kg(-1) followed by thiopentone 3 mg x kg(-1)
Study: 9737654
Drug: Sodium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-channel blockers
Study: 9737654
Drug: Chronic antiarrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiarrhythmic therapy
Study: 9737654
Drug: Recognition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognition of proarrhythmia and withdrawal of offending agents
Study: 6804113
Drug: Long-acting propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol, 160 mg once daily for 4 weeks
Study: 6804113
Drug: Standard propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard propranolol, 40 mg four times daily for 4 weeks
Study: 31222951
Drug: Roxadustat 50
Normalized name: Roxadustat 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 50 or 70 mg three times weekly (ESA-Naïve group)
Study: 31222951
Drug: Roxadustat 70
Normalized name: Roxadustat 70 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 70 or 100 mg three times weekly (ESA-Converted group)
Study: 28744099
Drug: Verinurad (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (40 mg, single dose)
Study: 28744099
Drug: Verinurad (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (10 mg, multiple dose)
Study: 28744099
Drug: Verinurad (≥2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (≥2 mg)
Study: 28744099
Drug: Verinurad (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (single and multiple doses)
Study: 28744099
Drug: Verinurad (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (multiple daily doses)
Study: 27046160
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 or 60 mg twice daily)
Study: 19938709
Drug: Synthetic colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic colloid solutions
Study: 17674759
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Postoperative management at one week after operation, then weekly for the first and second month, bi-weekly for the third and fourth month, and monthly after the fifth month.
Study: 17674759
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Postoperative management at two weeks after operation, then bi-weekly for the first and second month, monthly from third to fifth month, and bi-monthly after sixth month.
Study: 15206017
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg procaine hydrochloride
Study: 11199949
Drug: Alprazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2 mg/day)
Study: 9472839
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg/24 hr for 8 weeks
Study: 20957498
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily
Study: 7594335
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg twice daily
Study: 2174652
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 0.75% prilocaine hydrochloride with 5 ml 8.4% sodium bicarbonate
Study: 25209545
Drug: In-feed ZnO
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-feed ZnO at 3000 mg/kg
Study: 25209545
Drug: Control feed
Normalized name: SYRINGE,FEEDING,THUMB CONTROL RING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control feed with 100 mg ZnO/kg
Study: 25046055
Drug: Mitiglinide 10
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10 mg and voglibose 0.2 mg (three-times-daily before each meal)
Study: 25046055
Drug: Mitiglinide 10
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10 mg and voglibose 0.2 mg (twice-daily before breakfast and dinner)
Study: 22119455
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 2 × 2 (160/4.5 μg)
Study: 22119455
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 1 × 2 (160/4.5 μg)
Study: 14716472
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, single oral dose)
Study: 10024837
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat (2.5, 5, or 10 mg BID)
Study: 10024837
Drug: Oral quinapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinapril (10, 20, or 40 mg OD)
Study: 10024837
Drug: Oral quinapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinapril
Study: 752875
Drug: Adjuvant BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant BCG immunotherapy (intradermal and oral BCG)
Study: 21774288
Drug: Fentanyl-propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fentanyl-propofol group (1 mcg/kg fentanyl)
Study: 15175887
Drug: Dorsal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal block splinting of the PIP joint with daily active exercise (Group B)
Study: 11775046
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors (SSRIs, N = 748)
Study: 9863097
Drug: Theo-polyphenols (TP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-polyphenols (TP) treatment
Study: 7934599
Drug: Topical bovine
Normalized name: thrombin topical bovine 5000 intl units topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bovine collagen applied weekly to the wound
Study: 3391871
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (ES) 500 mg tid
Study: 27921320
Drug: Amiselimod 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod 0.8 mg
Study: 25195813
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT, aspirin and clopidogrel)
Study: 23449607
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg for 26 weeks
Study: 21814477
Drug: Control (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Group A): Intralipid(®) 2 ml as a placebo 15 min before the cervical plexus block and at the end of the surgery
Study: 21814477
Drug: Routine analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine analgesia (Group B): Placebo 15 min before the cervical plexus block and flurbiprofen 50 mg at the end of the surgery
Study: 21814477
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia (Group C): Intravenous flurbiprofen 50 mg 15 min before the cervical plexus block and a placebo at the end of the surgery
Study: 17043939
Drug: 10 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mmHg CO(2) pneumoperitoneum + intraperitoneal normal saline infusion (Group C)
Study: 15853118
Drug: DHA enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA enriched foods (2 g fish oils)
Study: 15853118
Drug: Soya-protein (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-protein (25 g)
Study: 26883689
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU vagitocin (oxytocin containing gel)
Study: 24998009
Drug: Pump treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump treatment
Study: 22904246
Drug: OMT (Osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT (Osteopathic Manipulative Treatment)
Study: 12601105
Drug: IFNbeta treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta treatment (Avonex, Betaferon, Rebif-22)
Study: 12601105
Drug: Persistent NAb+
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent NAb+ (neutralizing antibodies positive)
Study: 12601105
Drug: NAb- (neutralizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAb- (neutralizing antibodies negative)
Study: 1854617
Drug: Low 6‐mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low 6‐mercaptopurine (6‐MP) doses due to neutropaenia and higher doses of Mtx
Study: 1854617
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy in maximally tolerated doses
Study: 6147940
Drug: beta 1‐blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 1‐blockade (100 mg metoprolol)
Study: 6147940
Drug: beta 1/2‐blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 1/2‐blockade (2 mg levobunolol)
Study: 30777651
Drug: OnabotulinumtoxinA (BoNT)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA (BoNT) prior to cognitive behavioral therapy (CBT)
Study: 30777651
Drug: Placebo prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prior to cognitive behavioral therapy (CBT)
Study: 26702121
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU daily oral vitamin D3 supplementation
Study: 26702121
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU daily oral vitamin D3 supplementation
Study: 15845315
Drug: Combined Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Cognitive Behavioral Therapy and Contingency Management (CBT+CM)
Study: 15845315
Drug: Culturally Tailored
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Tailored Cognitive Behavioral Therapy (GCBT)
Study: 12821551
Drug: Electrophysiologically (EP)‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically (EP)‐guided therapy
Study: 12821551
Drug: No EP‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EP‐guided therapy
Study: 12821551
Drug: No EP-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EP-guided therapy
Study: 12821551
Drug: Serial EP-guided
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial EP-guided drug testing
Study: 10382127
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) triple therapy
Study: 10382127
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth pectin (CBP) triple therapy
Study: 10382127
Drug: CBS quadruple
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS quadruple therapy
Study: 10382127
Drug: CBP quadruple
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP quadruple therapy
Study: 8916625
Drug: No-couples-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-couples-treatment control group
Study: 1919540
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human interferon‐gamma (rIFN gamma) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks
Study: 1919540
Drug: no anti‐viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: no anti‐viral therapy (controls)
Study: 31033141
Drug: Wilms' tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wilms' tumor 1 peptide‐loaded dendritic cells (DCs) and OK‐432 adjuvant combined with conventional chemotherapy
Study: 21712700
Drug: Pirfenidone (PFD)
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone (PFD) 1800 mg/day for 6 months
Study: 17123214
Drug: Multidisciplinary in‐patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary in‐patient treatment programme
Study: 17123214
Drug: Multidisciplinary functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary functional restoration treatment for patients with high risk of chronification
Study: 11573589
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-PTC group
Study: 11573589
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-TOF group
Study: 11573589
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid enriched solution (AMIPAREN) infusion in AA-PTC group
Study: 11573589
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid enriched solution (AMIPAREN) infusion in AA-TOF group
Study: 8332615
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cocaine (2 mg/kg)
Study: 8332615
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cocaine (1 mg/kg)
Study: 27196998
Drug: Pre-hospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-hospital ticagrelor 180 mg loading dose
Study: 27196998
Drug: In-hospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-hospital ticagrelor 180 mg loading dose
Study: 18251358
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol cream